Manulife (Manufacturers Life Insurance)
URGN icon

Manulife (Manufacturers Life Insurance)’s UroGen Pharma URGN Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Sell
10,909
-44,777
-80% -$898K ﹤0.01% 2467
2025
Q4 		$1.29M Buy
55,686
+19,749
+55% +$428K ﹤0.01% 1729
2025
Q3 		$717K Sell
35,937
-1,539
-4% -$27.6K ﹤0.01% 2040
2025
Q2 		$513K Sell
37,476
-706
-2% -$6.78K ﹤0.01% 2166
2025
Q1 		$422K Buy
38,182
+696
+2% +$7.42K ﹤0.01% 2222
2024
Q4 		$399K Buy
37,486
+24,006
+178% +$287K ﹤0.01% 2342
2024
Q3 		$171K Buy
13,480
+178
+1% +$2.64K ﹤0.01% 2719
2024
Q2 		$223K Sell
13,302
-19,219
-59% -$273K ﹤0.01% 2557
2024
Q1 		$488K Buy
32,521
+21,805
+203% +$356K ﹤0.01% 2224
2023
Q4 		$161K Buy
+10,716
New +$139K ﹤0.01% 2694
2022
Q1 		– Sell
-11,924
Closed -$113 – 3189
2021
Q4 		$113 Sell
11,924
-330
-3% -$4.65K ﹤0.01% 3037
2021
Q3 		$206K Sell
12,254
-664
-5% -$10.5K ﹤0.01% 2965
2021
Q2 		$197K Buy
12,918
+536
+4% +$9.69K ﹤0.01% 3116
2021
Q1 		$241K Sell
12,382
-117
-0.9% -$2.48K ﹤0.01% 2761
2020
Q4 		$225K Buy
12,499
+579
+5% +$12.1K ﹤0.01% 2706
2020
Q3 		$230K Hold
11,920
– – ﹤0.01% 2481
2020
Q2 		$303K Sell
11,920
-405
-3% -$9.9K ﹤0.01% 2248
2020
Q1 		$220K Buy
12,325
+543
+5% +$14.7K ﹤0.01% 2265
2019
Q4 		$352K Sell
11,782
-381
-3% -$10.4K ﹤0.01% 2246
2019
Q3 		$292K Buy
12,163
+561
+5% +$18.3K ﹤0.01% 2335
2019
Q2 		$417K Buy
+11,602
New +$428K ﹤0.01% 2156

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s URGN Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its UroGen Pharma (URGN) stake by 80% in Q1 2026, selling an estimated $898K and leaving 10,909 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #2467.

Manulife (Manufacturers Life Insurance) first reported a position in URGN in Q2 2019 and has held it in 21 quarters since. The position peaked at $1.29M in Q4 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 10,909 shares of UroGen Pharma worth $196K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 44,777 UroGen Pharma shares in Q1 2026, an estimated $898K.
  • UroGen Pharma made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2467 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in UroGen Pharma in Q2 2019 and has held it in 21 quarters since.
  • Manulife (Manufacturers Life Insurance)'s UroGen Pharma position peaked at $1.29M in Q4 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.